Lenalidomide Ester Prodrug for Smoother Plasma Exposure
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current multiple myeloma treatments using thalidomide, lenalidomide, and pomalidomide suffer from hematologic toxicity, venous thrombosis, and significant plasma drug concentration variation, leading to dose-limiting factors and myelosuppression.
Innovation Solution
Development of dihydro-2H-isoindole ester compounds with specific structural modifications to improve pharmacokinetics, resulting in smoother absorption and sustained therapeutic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If lenalidomide is used at high dose to achieve sufficient therapeutic effect, then anti-tumorous efficacy is improved, but hematologic toxicity and myelosuppression worsen
Solution Approach 1:
The patent modifies the pharmacokinetic parameters of immunomodulators by introducing ester prodrugs that undergo hydrolysis to release active metabolites. This changes the concentration-time profile to achieve sustained therapeutic levels without excessive peak concentrations, thereby maintaining efficacy while reducing dose-limiting toxicities.
Solution Approach 2:
The ester prodrug structure is designed to be converted in vivo to the active immunomodulator through hydrolysis. This preliminary action allows the drug to be administered in a modified form that improves permeability and achieves smoother absorption, preventing the harmful effects of rapid high-concentration release.
2Speed
If lenalidomide is administered to achieve rapid therapeutic effect, then treatment speed is improved, but plasma drug concentration variation increases leading to dose-limiting toxicity
Solution Approach 1:
The patent employs ester prodrugs with different chain lengths and structures that dynamically release the active immunomodulator at controlled rates. This dynamic release mechanism smooths out plasma concentration fluctuations while maintaining rapid overall treatment effect, resolving the contradiction between speed and stability.
3Reliability
If existing immunomodulators are used to treat multiple myeloma, then anti-tumorous effect is achieved, but venous thrombosis and hematologic toxicity occur as adverse reactions
Solution Approach 1:
By modifying the pharmacokinetic parameters through ester prodrug design, the patent achieves sustained drug release that avoids the high peak concentrations associated with venous thrombosis and hematologic toxicity, while maintaining the anti-tumorous effect through adequate exposure over time.
Data Source
Figure 1~2
Figure 3~4
AI summary
The present invention discloses a dihydro-2H-isoindole ester compound of the general structural formula: The present invention also provides a method of preparing the dihydro-2H-isoindole ester compound and use thereof for preparation of a drug for treating multiple myeloma. The dihydro-2H-isoindole ester compound of the present invention has good permeability and, when orally administered, is absorbed and exerts a therapeutic effect in a steady and smooth manner. Due to the distinct absorption and metabolism behavior, the compound of the present invention possesses pharmacokinetic properties that can better address clinical needs, when compared to the existing drugs.